The 2018 Christmas TraveLeague luncheon supports fara — Friedreich Ataxia Research Association.
What is Friedreich Ataxia?
Friedreich Ataxia (FA) is a debilitating, life shortening degenerative neuro-muscular disorder, which affects about 1 in 30,000 people in Australia and New Zealand. It is most commonly diagnosed between the ages of 5 and 18 years and robs children and young adults of their mobility.
Friedreich Ataxia leads to loss of muscle co-ordination, fatigue, vision impairment, hearing loss and slurred speech, scoliosis (curvature of the spine), diabetes and serious heart conditions. It is caused by an inherited genetic mutation that limits the production of a protein called frataxin. 1 person in 90 is a carrier and doesn’t even know it until it affects their family.
Although there has been significant progress towards treatments, today there is no cure.
Who is fara?
The Friedreich Ataxia Research Association (fara) is a not-for-profit organisation that supports research into treatments and a cure for Friedreich Ataxia. fara does not receive State or Commonwealth Government support and relies largely on the family and friends of Friedreich Ataxia patients and generous businesses within Australia and New Zealand to fund its research programs.
Our priorities are to:
- Identify and fund the most promising research and cutting edge therapies
- Support the Friedreich Ataxia patient clinics
- Promote knowledge sharing and collaboration within the scientific community and medical profession
- Engage with the Friedreich Ataxia patient community and their families
- Raise funds through corporate partnerships and community fundraising
- Raise awareness of Friedreich Ataxia within the community and scientific and medical professions
Since its establishment in 2003, fara has funded over $3.5m in scientific research.
Visit the website: fara.org.au